Cisplatin (CDDP: cis-diamminedichloroplatinum) resistance is a major hurdle in the treatment of human ovarian cancer (OVCA). A better understanding of the mechanisms of CDDP resistance can greatly improve therapeutic outcome for patients. A determinant of CDDP sensitivity in OVCA, p53, is activated by checkpoint kinase 1 (Chk1) in response to DNA damage. Although the oncogenic phosphatase protein phosphatase magnesium-dependent 1 (PPM1D) can deactivate both p53 and Chk1 through sitespecific dephosphorylation, whether PPM1D has a role in CDDP resistance is unknown. Here, using pair-matched wild-type p53 CDDP-sensitive (OV2008) and -resistant (C13*) cells, and p53-compromised CDDP-resistant cells (A2780cp, OCC-1, OVCAR-3 and SKOV3), we have demonstrated (i) the existence of site-specific differences in phospho-Ser-Chk1 content between sensitive and resistant cells in response to CDDP; (ii) PPM1D, but not phosphoinositide-3-kinase-related kinase (ataxia telangiectasia and Rad3 related protein (ATR)), is important in the regulation of CDDP-induced Chk1 activation and OVCA cell chemosensitivity; (iii) PPM1D downregulation sensitizes resistant cells to CDDP primarily by activating Chk1 and p53. Our findings establish for the first time that PPM1D confers CDDP resistance in OVCA cells through attenuating CDDP-induced, Chk1-mediated, p53-dependent apoptosis. These findings extend the current knowledge on the molecular and cellular basis of cisplatin resistance and offer the rationale for PPMID as a potential target for treatment of chemoresistant OVCA.
Introduction
Ovarian cancer (OVCA) is the most common gynecological malignancies and the fifth most frequent cause of cancer death in women. It ranks second among gynecological cancers in the number of new cases and the first in the number of deaths each year (Canadian Cancer Society, 2009 ). Cisplatin (CDDP: cis-diamminedichloroplatinum) and its derivatives are the most widely used chemotherapeutic agent in the treatment of OVCA. It is a DNA-damaging agent, which creates DNA adducts, causing the activation of several pathways that culminate in apoptosis (Perego et al., 1996) . Drug resistance is a major obstacle to successful treatment of human malignancies. CDDP resistance is multifactorial and may result from functional changes in OVCA cells, such as enhanced-DNA damage repair, decreased-drug accumulation and altered metabolism, and loss of apoptotic capacity (Mistry et al., 1992; Jekunen et al., 1994; Perego et al., 1996; Perego et al., 2003) . However, the precise mechanisms of CDDP resistance in human OVCA remain unknown.
The phosphoinositide-3-kinase-related kinase, ataxia telangiectasia and Rad3 related protein (ATR), has an important role in the DNA damage response. ATR activates several proteins, leading to cell cycle arrest and allowing repair of damaged DNA. ATR preferentially phosphorylates serine (S) or threonine (T) residues followed by glutamine (Q) (Capasso et al., 2002; Traven and Heierhorst, 2005) . Checkpoint kinase 1 (Chk1), a S/T kinase and important downstream target of ATR, is a G 2 / M cell cycle checkpoint regulator (Graves et al., 2000; Busby et al., 2000) . Chk1 contains several SQ/TQ residues, including Ser 317 and Ser
345
, which are phosphorylated by ATR and are essential for optimal Chk1 kinase activity (Zhao and Piwnica-Worms, 2001 ). However, the exact role of Chk1 in CDDP resistance in human OVCA is unclear.
The tumor suppressor p53 is a transcription factor, activated by CDDP through a Ser 15 and Ser 20 phosphorylation-dependent mechanism, which increases its proapoptotic properties (Ko and Prives, 1996; Levine, 1997; Shieh et al., 1997; Shieh et al., 1999; Shieh et al., 2000; Damia et al., 2001; Yang et al., 2006) . p53 is phosphorylated by activated Chk1 at Ser 15 and Ser 20 , suppressing its binding to murine double minute 2 and its ubiquitination and proteasomal degradation (Honda et al., 1997; Qu et al., 2005) . Moreover, p53 phosphorylation results in its activation, causing the transcription of several genes, the products of which are antiproliferative, such as p21, which inhibits CDK1 and ultimately causes cell cycle arrest at the G 1 phase (Shieh et al., 2000; Jurvansuu et al., 2007) .
One of the transcriptional targets of p53 is the type 2C S/T phosphatase protein phosphatase magnesiumdependent 1 (PPM1D), also known as wild-type p53-induced phosphatase 1 (Wip1), which preferentially targets phospho-S and phospho-T residues in the SQ/TQ motifs and phospho-T residues in the TXY motifs (Lu et al., 2004; Yamaguchi et al., 2007; Lu et al., 2008; Chuman et al., 2008) . PPM1D expression is known to be induced by p53 in response to genotoxic stress (Choi et al., 2000) and it dephosphorylates both phospho-p53 at Ser 15 (Lu et al., 2007) and phospho-Chk1 at Ser 345 (Lu et al., 2005) , significantly reducing Chk1 kinase activity (Capasso et al., 2002) . It has been demonstrated that p38 MAP kinase, which activates p53 during genotoxic stress, is dephosphorylated by PPM1D, thereby negatively regulating the activation of p53 (Bulavin et al., 2002; Rauta et al., 2006) . Recent studies have shown that PPM1D also interacts with several proteins involved in numerous cellular processes: murine double minute 2 and murine double minute 4 in the DNA damage response (Lu et al., 2008; Zhang et al., 2009) ; UNG2 in base excision repair (Lu et al., 2004) ; and nuclear factorkB in the inflammatory response (Chew et al., 2009) . Moreover, PPM1D is overexpressed in a panel of ovarian clear cell adenocarcimomas (Hirasawa et al., 2003; Tan et al., 2009 ). Downregulation of PPM1D or the inhibition of its activity in PPM1D-overexpressing cells alone was sufficient to decrease their survival, even in the absence of genotoxic stress, suggesting that the cell survival is dependent on PPM1D expression and phosphatase activity (Tan et al., 2009) . However, the role of PPM1D in CDDP chemoresistance in OVCA cells, and if it is related to p53 and Chk1 regulation, is not well understood.
In the present study, we have examined the interaction between PPM1D, Chk1 and p53, and how PPMID regulates CDDP sensitivity in OVCA cells. We have demonstrated for the first time that PPM1D contributes to CDDP resistance in human OVCA cells by directly targeting Chk1 and p53, diminishing their activation and thereby reducing p53-dependent, CDDP-induced apoptosis.
Results

CDDP increases phospho-Ser
345
-Chk1 content in sensitive, but not resistant OVCA cells To examine whether Chk1 activation is dysregulated in resistant OVCA cells, we carried out time-course (0-10 mM CDDP; 0-6 h) and concentration-response (0-10 mM; 6 h) experiments with OV2008 cells and its resistant counterpart C13*. CDDP significantly increased phospho-Ser 345 -Chk1 content in OV2008, but not C13* cells (Figure 1a) . Analysis of phospho-Ser 345 -Chk1 content indicates significant effects of CDDP (Po0.001), duration of culture (Po0.001) and cell type (Po0.001). There was a highly significant, time-dependent increase in phospho-Ser 345 -Chk1 level in OV2008 cells (Po0.001, Figure 1a ) as well as a significant interaction between CDDP and culture duration (Po0.001), suggesting that the magnitude of CDDPinduced phospho-Ser 345 -Chk1 content is dependent on the treatment duration. This response is also concentration-dependent, and there were highly significant effects of cell line (Po0.001), CDDP treatment (Po0.001) and interaction between the two factors (Po0.001, Figure 1a ). In contrast, no difference in Chk1 content was detected (Figure 1a) , suggesting that the increased phospho-Ser 345 -Chk1 content in OV2008 was not due to increased substrate. In addition, the increased phosphoSer 345 -Chk1 level in OV2008, but not C13* cells in response to CDDP appeared to be substrate site-specific, as phospho-Ser 317 -Chk1 content in response to CDDP treatment was not significantly different between the two cell lines, irrespective of the duration of culture and concentration ( Figure 1a (Lu et al., 2005) . However, whether PPM1D-mediated Chk1 dephosphorylation is involved in CDDP chemoresistance has not been reported. To determine the expression of PPM1D in OVCA cells and its response to CDDP, we performed a time-course experiment (0-10 mM CDDP; 0-24 h) with OV2008 and C13* cells. In OV2008 cells, PPM1D content steadily increased, following CDDP treatment starting at 3 h (Po0.001), reaching a maximum at 9 h (Po0.001), when compared with the control. Thereafter, PPM1D level started to decline and it was significantly lower than the control at 24 h (Po0.001). Phospho-Ser 345 -Chk1 level followed a similar pattern, reaching a maximum at 12 h after CDDP treatment (Po0.001) and then sharply declined. In C13* cells, PPM1D levels sharply increased at 9 h (Po0.001). PPM1D level slightly decreased afterwards, but by 24 h, it was significantly higher than control (Po0.001). Again, Phospho-Ser 345 -Chk1 level followed a similar pattern, reaching a maximum level at 9 h (Po0.001) and steadily declined thereafter (Figure 1b ).
PPM1D is involved in the regulation of Chk1-mediated CDDP sensitivity To assess the role of PPM1D in the regulation of CDDP sensitivity, PPM1D in OV2008 and C13* cells was knocked down by siRNA (0-400 nM; 24 h) before CDDP challenge (0-10 mM; 12-24 h), and phospho-Ser content and apoptosis were determined. PPM1D downregulation significantly increased CDDP sensitivity in both OV2008 and C13* cells in a concentrationdependent manner, which was confirmed by poly (ADP-ribose) polymerase cleavage (Po0.001, Figure 2a ). Contrary to our expectation, however, phospho-Ser Furthermore, PPM1D overexpression in OV2008 cells with PPM1D cDNA or empty vector, followed by CDDP challenge (10 mM; 12 h), resulted in a significant reduction in CDDP-induced apoptosis, compared with the control (Po0.001), which was accompanied with significant decrease in phospho-Ser 345 -Chk1 and phospho-Ser 15 -p53 levels (Po0.001; Figure 2b ). To investigate whether the sensitization of C13* cells to CDDP following PPM1D knockdown is in some extent due to Chk1 activation, we knocked down both Chk1 (0-10 nM; 48 h) and PPM1D (0-400 nM; 24 h) in C13* cells, followed by CDDP treatment (0-10 mM; 24 h). PPM1D knockdown significantly sensitized C13* cells to CDDP-induced apoptosis, compared with the control (Po0.001), whereas the double knockdown of both PPM1D and Chk1 significantly reduced CDDPinduced apoptosis (Po0.001), but did not completely abolish CDDP sensitivity (Figure 3b ).
To assess if Chk1 deficiency affects CDDP sensitivity and cell cycle checkpoint, we performed flow cytometric analyses of CDDP response (0-10 mM; 24 h) of Chk1-deficient MDA-MB-DChk1 breast cancer cells compared with their parental cell line. Chk1 deficiency caused decreased sensitivity to CDDP, indicated by lack of increase in MDA-MB-231DChk1 cells in the sub-G 1 fraction compared with the control, and loss of cell cycle checkpoint, indicated by the absence of cell cycle arrest in the G 2 /M phase observed in the wt-MDA-MB-231 cells in response to CDDP. Furthermore, western analyses revealed that MDA-MB-231DChk1 cells had a significantly reduced phospho-Ser 15 -p53 content following CDDP treatment, compared with wt-MDA-MB-231 cells (Figure 3c ).
Involvement of PPM1D in CDDP-induced, p53-mediated regulation of chemosensitivity in OVCA cells To investigate whether the sensitization of C13* cells to CDDP following PPM1D knockdown is mediated by Chk1, but ultimately p53-dependent, we knocked down p53 (0-100 nM; 48 h), Chk1 (0-10 nM; 48 h) and PPM1D (0-400 nM; 24 h) in C13* cells followed by CDDP treatment (0-10 mM; 24 h). PPM1D knockdown significantly sensitized C13* cells to CDDP-induced apoptosis compared with the control (Po0.001), whereas the double knockdown of both PPM1D and Chk1 significantly reduced CDDP-induced apoptosis (Po0.001), but did not completely abolish CDDP sensitivity. The triple knockdown of PPM1D, Chk1 and p53 significantly reduced CDDP-induced apoptosis (Po0.001), and restored CDDP resistance in C13* cells (Figure 4) . To further explore this question and demonstrate that the observed phenomena are not cell line-specific, we reconstituted wt-p53 with adenoviral p53 or LacZ as control (0-10 MOI; 4 h) in several p53-compromised, CDDP-resistant OVCA cell lines (p53 mutant: A2780cp, OCC-1, OVCAR-3; p53 null: SKOV3) followed by PPM1D downregulation (0-400 nM; 24 h) and CDDP treatment (10 mM; 24 h). p53 reconstitution significantly sensitized resistant OVCA cells to CDDP-induced apoptosis (Po0.001) and PPM1D downregulation further enhanced CDDP sensitivity in A2780cp and OCC-1 cells (Po0.01), as well as OVCAR-3 and SKOV3 cells (Po0.05). However, PPM1D knockdown alone did not increase CDDP sensitivity, and enhanced CDDP sensitivity was only observed in the presence of wt-p53 ( Figure 5 ).
Effects of p53 and Chk1 downregulation on CDDPinduced cell cycle regulation in chemoresistant C13* cells To investigate the cell cycle regulation by CDDP in C13* cells and how this regulation might be altered following p53 or Chk1 downregulation, we conducted flow cytometric analyses of C13* cells in the presence or absence of CDDP. CDDP treatment significantly decreased the cell population in the G 1 phase, but increased the population in both the S and G 2 /M phases. p53 silencing did not alter the CDDP responses. As p53 activation in response to CDDP is reduced in resistant C13* cells (Figure 3a) , we did not expect any significant changes in the cell cycle in response to p53 downregulation and following CDDP treatment. However, Chk1 downregulation caused a significant decrease in S phase (Po0.05) and G 2 /M phase (Po0.01) in response to CDDP. None of the treatments altered the cell population in the sub-G 1 phase, indicating no sensitization of resistant C13* cells to CDDP, regardless of siRNA treatment (Figure 6 ). Although CDDP treatment enhanced cell cycle arrest of C13* cells at the S and G 2 /M phases, Chk1 downregulation significantly, but partially, rescued CDDP-induced cell cycle arrest, suggesting a possible involvement of a compensatory pathway (for example ATM/Chk2 pathway) in the DNA damage response (Supplementary Figure S1A) . Involvement of PPM1D in CDDP-induced, p53-mediated regulation of chemosensitivity in OVCA cells. PPM1D knockdown significantly enhanced CDDP-induced apoptosis in C13* cells (Po0.001), whereas knockdown of PPM1D and Chk1 partially, but significantly, reduced CDDP sensitivity (Po0.001), and the concomitant knockdown of PPM1D, Chk1 and p53 abolished CDDP-induced apoptosis (Po0.001). C13* cells were treated with p53 siRNA (0-100 nM, 48 h), Chk1 siRNA (0-10 nM, 48 h) and/or PPM1D siRNA (0-400 nM, 24 h) treated with CDDP (0-10 mM, 24 h), and PPM1D, Chk1, phospho-Ser 345 -Chk1, p53, phospho-Ser 15 -p53, b-actin contents and apoptosis were assessed (n ¼ 3). ***Po0.001 (vs respective CTL).
Discussion
In the present study, we examined the molecular basis of CDDP resistance using a pair-matched CDDP-sensitive (OV2008) and -resistant (C13*) OVCA cells and p53-compromised CDDP resistant OVCA cells (A2780cp, OCC-1, OVCAR-3 and SKOV3). We have demonstrated (i) the existence of site-specific differences in phospho-Ser-Chk1 content between sensitive and resistant cell lines in response to CDDP; (ii) PPM1D, but not ATR, is important in the regulation of CDDP-induced Chk1 activation and OVCA cell chemosensitivity; (iii) PPM1D downregulation sensitizes resistant OVCA cells to CDDP, primarily by activating Chk1 and p53. Our findings establish for the first time that PPM1D confers CDDP resistance in OVCA cells through attenuating CDDP-induced, Chk1-mediated, p53-dependent apoptosis.
Although a major hurdle in the treatment of human OVCA is chemoresistance, its underlying molecular mechanism is complex and not well understood (Sasaki et al., 2000; Yang et al., 2006; Yang et al., 2008; Fraser et al., 2008; Abedini et al., 2008; Abedini et al., 2010) . We have previously shown that CDDP induces apoptosis in sensitive human OVCA cells, but not their resistant counterparts (Sasaki et al., 2000; Abedini et al., 2008; Abedini et al., 2010) and that CDDP-induced apoptosis in sensitive OVCA cells is dependent on p53 activation, particularly p53 phosphorylation on Ser 15 and Ser 20 . It is believed that CDDPinduced DNA damage leads to activation of the DNA damage pathway, particularly the DNA damage sensor ATR. ATR, in turn, activates its effector Chk1 through phosphorylation of S-residue 317, which is required to achieve ATR-mediated Ser 345 phosphorylation (Wilsker et al., 2008) . Ser 345 phosphorylation is an essential phosphorylation site for Chk1 nuclear localization and retention. If the DNA damage is too serious to be repaired, ATR activates p53 through phosphorylation of Ser 15 and Ser 20 directly and indirectly through Chk1 (Graves et al., 2000; Capasso et al., 2002; Jiang et al., 2003; Yazlovitskaya and Persons, 2003; Qu et al., 2005; Ouyang et al., 2009; Rong et al., 2010) . It has also been established that the p53-responsive phosphatase PPM1D modulates the action of ATR by direct dephosphorylation of phospho-Ser 15 of p53 and phosphoSer 345 of Chk1 (Choi et al., 2000; Lu et al., 2004; Lu et al., 2005; Yamaguchi et al., 2007; Lu et al., 2008) . However, the impact of p53 and Chk1 deactivation by PPM1D on CDDP sensitivity in human OVCA has not been studied. In the present study, we provide a novel mechanism of CDDP chemoresistance in human OVCA involving the oncogenic phosphatase PPM1D, Chk1 and p53, furthering the current knowledge and adding to the previously illustrated underlying mechanisms of CDDP resistance in human OVCA.
Chk1 could have both pro-and anti-apoptotic roles in resistant cancer cells, depending on their p53 status (Bunch and Eastman, 1996; Shao et al., 1997; Sugiyama et al., 2000; Playle et al., 2002; Carrassa et al., 2004; Chen et al., 2006; Reinhardt et al., 2007; Wagner and Karnitz, 2009; Pan et al., 2009) . Our working hypothesis assumes Chk1 is pro-apoptotic and acts in a p53-dependent manner. The dimorphic nature of Chk1 (proor anti-apoptotic) depends primarily on the presence of a functional p53 signaling pathway, a key mediator of its pro-apoptotic activity. However, in the studies where Chk1 inhibition lead to sensitization to several cytotoxic agents, the cell lines used had aberrant p53 signaling due to deficiency or mutation (Bunch and Eastman, 1996; Shao et al., 1997; Sugiyama et al., 2000; Playle et al., 2002; Carrassa et al., 2004; Chen et al., 2006; Reinhardt et al., 2007; Wagner and Karnitz, 2009; Pan et al., 2009) . Our data suggest that the delay in Chk1 activation PPM1D knockdown did not sensitize A2780cp (p53 mutant), OCC-1 (p53 mutant), OVCAR-3 (p53 mutant) and SKOV3 (p53 null) cells to CDDP-induced apoptosis. However, although wt-p53 reconstitution significantly sensitized resistant OVCA cells to CDDP (Po0.001), combined PPM1D downregulation and p53 reconstitution significantly enhanced CDDP-induced apoptosis (Po0.01 for A2780cp and OCC-1 cells; Po0.05 for OVCAR-3 and SKOV3), which was associated with an increase in phosphoSer 15 -p53 content. A2780cp, OCC-1, OVCAR-3 and SKOV3 cells were infected with adenoviral p53 (0-10 MOI; 5 h), treated with PPM1D siRNA (0-400 nM, 24 h) and cultured with CDDP (10 mM, 24 h). PPM1D, p53, phospho-Ser 15 -p53, b-actin contents and apoptosis were assessed (n ¼ 3). *Po0.05 **Po0.01 and ***Po0.001 (vs CDDP alone).
(Ser 345 phosphorylation) in response to CDDP observed in resistant OVCA cells, which cannot be substantiated by aberrant upstream signaling (ATR activation and Ser 317 phosphorylation), is associated with CDDP resistance and synchronized temporally with PPM1D accumulation. Our findings appear not to be in accord with the findings that Ser 345 phosphorylation in Chk1 is dependent on the activation of Chk1 at the Ser 317 site in colorectal cancer cells following hydroxyurea treatment or ionizing radiation (Wilsker et al., 2008) . Our data show that ATR activation and phospho-Ser Although the reason (s) for these apparent differences is not immediately clear, the possibility that this reflects variations in cancer cell type, genetic background or treatment remains to be investigated.
Moreover, we did not observe any sensitization of resistant OVCA cells to CDDP following siRNAmediated Chk1 downregulation, whereas Chk1 knockout lead to a loss of G 2 /M checkpoint in MDA-MB231DChk1 breast cancer cells, a response associated with the virtual absence of p53 activation (Ser 15 phosphorylation) and decreased CDDP sensitivity. Moreover, Chk1 downregulation in resistant OVCA cells significantly abrogated CDDP-induced G 2 /M cell cycle arrest. Our findings strongly support the hypothesis that Chk1 confers CDDP sensitivity in our cells, which contain a functional p53.
Under normal physiological conditions, PPM1D has a crucial role in restoring cellular homeostasis through promoting cell cycle re-entry following DNA repair by deactivating several DNA damage sensors, stress sensors and checkpoint proteins, including ATR, ATM, p38 MAPK, Chk1, Chk2 and p53 (Lu et al., 2005; Lu et al., 2008) . However, in pathophysiological conditions such as cancer, we believe that PPM1D dampens the DNA damage response through sustained inhibition of its targets, thus promoting cell survival and resistance to chemotherapy. This certainly holds true in our system, as downregulation of PPM1D sensitized resistant OVCA cells to CDDP and further enhanced CDDP-induced apoptosis in sensitive OVCA cells. Moreover, overexpression of PPM1D in sensitive OVCA cells reduced CDDP sensitivity, which was associated with decreased Chk1 and p53 activation. PPM1D regulates several activators of p53 in the DNA damage pathway other than Chk1. It could be argued that downregulation of PPM1D in resistant OVCA cells alleviates the inhibition on those kinases along with Chk1, facilitating p53-dependent, CDDPinduced apoptosis. However, our data clearly demonstrate that Chk1 has a significant part in sensitizing resistant OVCA cells to CDDP following PPM1D downregulation.
Chk1 activates p53 in response to DNA damage through direct phosphorylation of Ser 15 and Ser 20 (Shieh et al., 2000; Qu et al., 2005) , thus protecting p53 from murine double minute 2-mediated proteasomal degradation (Honda et al., 1997; Lakin and Jackson, 1999) . Our data suggest that p53 activity is critical in mediating Chk1 pro-apoptotic signal. Although partial, but significant, decrease in CDDP sensitivity of wt-p53 resistant OVCA cells following downregulation of both PPM1D and Chk1, downregulation of PPM1D, Chk1 and p53 led to complete suppression of CDDP-induced apoptosis in these cells. Moreover, the downregulation of PPM1D in p53-compromised resistant OVCA cells significantly enhanced CDDP-induced apoptosis only, following wt-p53 reconstitution. Thus, facilitation of CDDP-induced apoptosis by PPMID downregulation may involve activation of both Chk1 and p53, and may ultimately be dependent on p53 status.
Both p53 and Chk1 can regulate the cell cycle at different phases, where p53 controls the G 1 checkpoint through the transcriptional regulation of the CDK inhibitor p21 (Shieh et al., 2000; Jurvansuu et al., 2007) , and Chk1 regulates the critical transition from the G 2 to the M phase through phosphorylationdependent inactivation of CDC25 phosphatases (Graves et al., 2000; Busby et al., 2000) . Our findings suggest that, p53 activation in response to CDDP is reduced in chemoresistant C13* cells, and p53 knockdown failed to significantly influence CDDP-induced cell cycle regulation. In contrast, Chk1 downregulation significantly, but incompletely, abrogated CDDP-induced G 2 /M cell cycle arrest. Given the complexity of the DNA damage response and its involvement of several proteins, we cannot exclude that other DNA damage pathways which converge on the G 2 /M checkpoint (that is, ATM/Chk2 pathway) could be at play. This may explain the partial abrogation of CDDP-induced G 2 / M checkpoint following Chk1 knockdown.
In summary, the present studies have established a novel role for PPM1D in the regulation of CDDPinduced apoptosis and chemosensitivity in human OVCA cells. We have demonstrated that PPMID, through dephosphorylation and inactivation of Chk1 and p53, confers CDDP chemoresistance. To facilitate our future investigation on the precise role of PPM1D in CDDP resistance in OVCA cells, we proposed a hypothetical model (Figure 7) . In sensitive OVCA cells, CDDP induces Chk1 and p53 activation, whereas PPM1D level is tightly regulated. However, in chemoresistant cells, sustained PPM1D expression suppresses the activity of both Chk1 and p53, thereby contributing to CDDP resistance in OVCA cells. It is worthy to mention that the expression of PPM1D in response to CDDP may be induced by factors other than p53. Our data identify PPM1D as a potential novel therapeutic target in the treatment of chemoresistant human OVCA. However, although cell lines provide a convenient way to examine the molecular mechanisms involved in CDDP sensitivity, our findings have to be verified in an in vivo model to confirm the validity of this hypothesis. -ATR and anti-PPM1D, and mouse monoclonal antibodies, anti-GAPDH, were from Abcam (Cambridge, MA, USA) and anti-b-Actin from Cedarlane Laboratories (Burlington, ON, Canada). Goat anti-mouse and goat anti-rabbit secondary antibodies were from Bio-Rad Laboratories (Hercules, CA, USA). Control siRNA was from Dharmacon (Lafayette, CO, USA). siRNA constructs were: Chk1, Applied Biosystems (Foster City, CA, USA) and Qiagen (Valencia, CA, USA); PPM1D, Santa Cruz Biotechnology and Qiagen; p53, Cell Signaling Technology and Qiagen. pCMV6-XL5 vector containing wt-PPM1D cDNA clone and empty pCMV6-XL5 vector were from Origene (Rockville, MD, USA). Propidium iodide was from Roche Applied Sciences (Penzberg, Germany). Lipofectamine, Lipofectamine 2000, Lipofectamine Plus transfection reagents, RNase A and N,N,N 0 ,N 0 -tetramethyl-ethane-1,2-diamine (TEMED) were from Invitrogen (Carlsbad, CA, USA). wt-p53 and LacZ adenovirus were synthesized at the University of Ottawa Adenoviral Core Facility (Ottawa, ON, Canada).
Materials and methods
Reagents
Cell lines and culture CDDP-sensitive (OV2008 (wt-p53)) and -resistant (C13* (wt-p53), A2780cp (p53 mutant), OCC-1 (p53 mutant), OVCAR-3 (p53 mutant) and SKOV3 (p53 null)) human OVCA cell lines, gifts from Drs Rakesh Goel and Barbara Vanderhyden (Ottawa Regional Cancer Center, Ottawa, ON, Canada), were cultured as previously reported Abedini et al., 2010) . OV2008 cells and their resistant counterparts C13* cells are of ovarian endometrioid adenocarcinoma origin with squamous differentiation. A2780cp and OCC-1 cells are from undifferentiated ovarian carcinoma tumors. SKOV3 cells are of clear cell carcinoma origin (Shaw et al., 2004) . None of the cells used in this study overexpress PPM1D. Human breast cancer cell lines (wt-MDA-MB-231 and MDA-MB-231DChk1; generously provided by Dr Allan Eastman, Dartmouth Medical School, Hanover, NH, USA) were cultured as previously reported (Zhang et al., 2008) . Following the indicated treatments, the cells were harvested for analysis.
